Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Key Points Malignant cells from patients with AML expose danger signals on the plasma membrane regardless of chemotherapy. Such danger signals correlate with markers of a clinically relevant tumor-specific immune response and with improved disease outcome.